Skip to main content

Perceptive Advisors — Portfolio, Page 7

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

224
Companies
$26.6B
Total invested
$135.1M
Avg. check
17
Industries
Biotechnology 21Health Care 16Life Science 9Medical 8Pharmaceutical 8Therapeutics 7+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 145168 of 224
DarioHealth
September 2025

DarioHealth is a digital therapeutics company engaged in the development and commercialization of patented and proprietary technology.

Health Care · New York$17.5M Post Ipo Equity
Satellos Bioscience
September 2025

Satellos Bioscience is a private regenerative medicine company developing novel therapeutics that stimulate or restore muscle regeneration.

Health Care · Toronto$754K Post Ipo Equity
Oruka Therapeutics
September 2025

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Biotechnology · Waltham$180.0M Post Ipo Equity
Avidity Biosciences
September 2025

Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.

Biotechnology · San Diego$690.0M Post Ipo Equity
Amylyx Pharmaceuticals
September 2025

Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.

Biotechnology · Cambridge$175.0M Post Ipo Equity
Rapport Therapeutics
September 2025

Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.

Biotechnology · Boston$250.0M Post Ipo Equity
Absci
July 2025

Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

Artificial Intelligence (AI) · Vancouver$50.0M Post Ipo Equity
Forte Biosciences
June 2025

Forte Biosciences is a biotechnology company that focuses on dermatology.

Biotechnology · Sherman Oaks$75.0M Post Ipo Equity
Taysha Gene Therapies
May 2025

Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.

Biotechnology · Dallas$200.0M Post Ipo Equity
Zucara Therapeutics
May 2025

Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.

Biotechnology · Vancouver$5.0M Series B
Merida Biosciences
April 2025

Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.

Biotechnology · Cambridge$121.0M Series A
Edgewise Therapeutics
April 2025

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Biopharma · Boulder$200.0M Post Ipo Equity
Nuvation Bio
March 2025

Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.

Biotechnology · New York$150.0M Post Ipo Debt
VitalConnect
February 2025

VitalConnect offers wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations.

Biotechnology · San Jose$100.0M Series Unknown
Inhibrx
January 2025

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

Biotechnology · La Jolla$150.0M Post Ipo Debt
Alector
November 2024

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

Biotechnology · San Francisco$50.0M Post Ipo Debt
Beta Bionics
November 2024

Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.

Biotechnology · Irvine$60.0M Series E
Axonis Therapeutics
October 2024

Axonis Therapeutics is a neuro-focused biotechnology company that focuses on the development of novel neuromedicines.

Biotechnology · Boston$115.0M Series A
Genome Medical
September 2024

Genome Medical is a telegenomics technology and services company allowing access to genomic-based medicine.

Genetics · South San Francisco$75.3M Series D
Relay Therapeutics
September 2024

Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.

Biotechnology · Cambridge$200.0M Post Ipo Equity
Earli
August 2024

Earli develops genetic constructs for early cancer detection and targeted therapy.

Biotechnology · South San FranciscoSeries Unknown
scPharmaceuticals
August 2024

ScPharmaceuticals is a biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery.

Biotechnology · Lexington$125.0M Post Ipo Debt
Day One Biopharmaceuticals
July 2024

Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.

Biopharma · South San Francisco$175.0M Post Ipo Equity
IDEAYA Biosciences
July 2024

IDEAYA Biosciences is an oncology-focused biotechnology company that develops therapeutics for patients with genetically-defined cancers.

Biotechnology · South San Francisco$263.0M Post Ipo Equity

Where Perceptive Advisors invests

Biotechnology21
Health Care16
Life Science9
Medical8
Pharmaceutical8
Therapeutics7

About Perceptive Advisors's portfolio

How many companies has Perceptive Advisors invested in?

Perceptive Advisors has invested in 224 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Perceptive Advisors invest in?

Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Life Science, Medical, Pharmaceutical. The firm invests across 17 different industry categories.

What is Perceptive Advisors's largest investment?

Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post Ipo Equity round. Perceptive Advisors's total known invested capital is $26.6B.

What is the average investment size for Perceptive Advisors?

Perceptive Advisors's average investment size is $135.1M across its portfolio of 224 companies.

What are Perceptive Advisors's most recent investments?

Recent Perceptive Advisors portfolio additions include DarioHealth, Satellos Bioscience, Oruka Therapeutics, Avidity Biosciences, Amylyx Pharmaceuticals. These companies were founded in 2020 or later.

Reach the founders behind these 224 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →